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degradation via enhanced binding to the
Raptor-CUL4B complex. mTORC1 or
glutamate receptor inhibition stabilizes
deamidated 4E-BP2. Moreover,
deamidated 4E-BP2 regulates the
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The translation initiation repressor 4E-BP2 is deami-
dated in the brain on asparagines N99/N102 during
early postnatal brain development. This post-transla-
tional modification enhances 4E-BP2 association
with Raptor, a central component of mTORC1 and al-
ters the kinetics of excitatory synaptic transmission.
We show that 4E-BP2 deamidation is neuron spe-
cific, occurs in the human brain, and changes 4E-
BP2 subcellular localization, but not its disordered
structure state. We demonstrate that deamidated
4E-BP2 is ubiquitinated more and degrades faster
than the unmodified protein. We find that enhanced
deamidated 4E-BP2 degradation is dependent on
Raptor binding, concomitant with increased associa-
tion with a Raptor-CUL4B E3 ubiquitin ligase com-
plex. Deamidated 4E-BP2 stability is promoted by in-
hibiting mTORC1 or glutamate receptors. We further
demonstrate that deamidated 4E-BP2 regulates the
translation of a distinct pool ofmRNAs linked to cere-
bral development, mitochondria, and NF-kB activity,
and thus may be crucial for postnatal brain develop-
ment in neurodevelopmental disorders, such as ASD.
INTRODUCTION
Since their discovery (Pause et al., 1994) as repressors of eu-
karyotic translation initiation factor 4E (eIF4E), eIF4E-binding
proteins (4E-BPs) have been implicated in cancer progression
(Petroulakis et al., 2009), innate immunity (Colina et al., 2008),
circadian rhythms (Cao et al., 2013), learning and memory
(Banko et al., 2005, 2007), and, more recently, autism spectrum
disorders (ASDs) (Gkogkas et al., 2013). Cap-dependent transla-
tion initiation requires the binding of eIF4E to the 50 end cap of the3620 Cell Reports 29, 3620–3635, December 10, 2019 ª 2019 The A
This is an open access article under the CC BY license (http://creativeUTRs ofmRNAs (Hinnebusch et al., 2016; Sonenberg andHinne-
busch, 2009). This event brings about the formation of the eIF4F
translation initiation complex comprising, in addition to eIF4E,
eIF4G (a scaffolding protein) and eIF4A (an mRNA helicase)
(Gkogkas et al., 2010). 4E-BPs in their hypo-phosphorylated
state inhibit eIF4F complex formation by competing with eIF4G
for binding to the dorsal surface on eIF4E (Matsuo et al., 1997;
Lukhele et al., 2013). Upon phosphorylation by the mamma-
lian/mechanistic target of rapamycin complex 1 (mTORC1) ki-
nase, 4E-BPs display a reduced affinity for eIF4E, leading to
increased eIF4F complex formation, and thus translation initiates
(Pause et al., 1994). This sophisticated signaling cascade, which
constitutes a rate-limiting step for protein synthesis, has evolved
to preferentially regulate the synthesis of specific proteins in
different cell types and tissues, via mRNA translational control
(Jung et al., 2014; Hinnebusch et al., 2016). There are three
mammalian 4E-BPs (4E-BP1, 4E-BP2, and 4E-BP3), and 4E-
BP2 is the paralog predominantly expressed in the mammalian
brain (Banko et al., 2005; Tsukiyama-Kohara et al., 2001; Bidi-
nosti et al., 2010b).
4E-BP2 is an intrinsically disordered protein (IDP), lacking ter-
tiary structure, but upon phosphorylation-induced folding, the
protein structure becomes stable (Bah et al., 2015). Phosphory-
lation of 4E-BP2 occurs in most tissues, including in the brain.
However, during postnatal brain development, 4E-BP2 phos-
phorylation decreases (Banko et al., 2005; Bidinosti et al.,
2010b), coinciding with an overall decrease in mTORC1
signaling (Bidinosti et al., 2010b). 4E-BP2 phosphorylation is
barely detectable in the adult brain (Banko et al., 2005; Bidinosti
et al., 2010b). Notably, in early postnatal brain development and
exclusively in brain tissue, 4E-BP2 undergoes post-translational
deamidation (persisting into adulthood) on asparagines N99 and
N102, which are converted to a mixture of aspartates and isoas-
partates (Bidinosti et al., 2010b). Because isoaspartates can
destabilize proteins, the enzyme L-isoaspartyl methyltransferase
(PIMT), which is highly active in the brain, catalyzes the conver-
sion of isoaspartates to aspartates (via the intermediate productuthor(s).
commons.org/licenses/by/4.0/).
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succinimide), and 4E-BP2was shown to be a PIMT substrate (Bi-
dinosti et al., 2010a). Asparagine deamidation is not catalyzed by
enzymes, but it can occur spontaneously and is accelerated by
alkaline pH (Robinson, 2002). The only two known examples of
enzymatic asparagine deamidation are linked to herpes simplex
virus (HSV). First, asparagine deamidation of the pattern recog-
nition receptor RIG-I (retinoic acid-induced gene I) by cellular
phosphoribosylformyglycinamide synthase (PFAS) during HSV
infection serves as a mechanism to avoid antiviral cytokine pro-
duction (He et al., 2015). Second, the HSV tegument protein
UL37 deamidates cellular cyclic guanosine monophosphate
(GMP)-AMP synthase (cGAS) to attenuate innate immunity
(Zhang et al., 2018).
Deamidated 4E-BP2 was shown to regulate the kinetics of
excitatory synaptic transmission in early postnatal brain devel-
opment (Bidinosti et al., 2010b), suggesting that it may be impor-
tant for synaptic function during that crucial developmental
period. N99/N102 deamidation decreases the capacity of 4E-
BP2 to compete with eIF4G and inhibit eIF4F complex formation,
and it also increases its binding to the mTORC1 protein Raptor
(Bidinosti et al., 2010b). The significance of enhanced Raptor
binding to deamidated 4E-BP2 remains unclear. In addition,
and given the pervasive role of 4E-BP2 in regulating brain func-
tion during development and adulthood (Gkogkas et al., 2013;
Cao et al., 2013; Bidinosti et al., 2010b; Banko et al., 2005), it
is crucial to elucidate the downstream effects of deamidated
4E-BP2 in regulating the translational landscape of mRNAs in
the brain.
Here, we demonstrate that 4E-BP2 deamidation occurs in
neurons but not glial cells and is also detected in the human
brain. Constitutively deamidated 4E-BP2 protein is less stable
than wild type (WT), and mTORC1 or glutamate receptor inhibi-
tion selectively promotes the accumulation of deamidated
4E-BP2 but not of unmodified protein. We reveal that the sus-
ceptibility of deamidated 4E-BP2 to proteasomal degradation
depends on increased Raptor binding and Cullin 4B (CUL4B)
protein abundance, leading to the enhanced formation of a
Raptor- CUL4B E3 ligase complex. Using unbiased translatome
mapping, we demonstrate that deamidated 4E-BP2 preferen-
tially regulates the synthesis of a distinct pool of mRNAs linkedFigure 1. Postnatal 4E-BP2 Deamidation Is Neuron Specific, Affects P
Disordered State
(A) Left: representative immunoblots of lysates from different days in vitro (DIV)
trypsinization of neuronal cultures, probed with antisera against the indicated prot
passage 1 (p.1) glial cells treated with l-phosphatase (l-PPase). Hsc70 is a loadin
of 4E-BP2 in brain tissue showing 3 distinct forms: 0D (no deamidation), 1D (N99D
4E-BP2 around the deamidation site, mTOR phosphorylation sites (T37/46), eIF4E
motif).
(B) Immunoblotting of lysates prepared from mouse brain and post-mortem huma
(B), red arrows indicate the position of the slow migrating deamidated forms of 4
680 (red) nm and a merged image are shown.
(C and D) Soma (C) and dendrites (D) fromdissociated DIV16 corticalmouse neuro
with antisera against FLAG- or HA-tags, followed by secondary antibodies (conjug
arrows marking distinct WT or 2D fluorescent puncta are shown in white; n = 8.
(E) Imaris-generated 2D histograms showing the quantification of fluorescent i
Pearson correlation coefficient of the colocalized volume of the red (2D) channel
(F) Ten superimposed DAMMINmodels, generated using the SAXS data from the
discrepancy (NSD) for WT and 2D recombinant proteins.
See also Figures S1, S2, and S3 and Tables S1 and S2.
3622 Cell Reports 29, 3620–3635, December 10, 2019to neuronal development, proliferation, glutathione and oxidore-
ductase activity, mitochondrial function, and nuclear factor
k-light-chain enhancer of activated B cells (NF-kB) activity.
Moreover, the overexpression of deamidated 4E-BP2 strongly
inhibits NF-kB activity. These data describe a previously uniden-
tified brain-specific translational control mechanism during early
postnatal brain development (persisting into adulthood), which
could be crucial for neurodevelopmental disorders.
RESULTS
Postnatal 4E-BP2 Deamidation Is Neuron Specific, but It
Does Not Alter Its Intrinsically Disordered State
To investigate the role of constitutively deamidated (aspara-
gine/aspartic acid; D99/D102) as compared to non-deami-
dated, unmodified 4E-BP2 (N99/N102) in the brain, we cultured
cortical neurons isolated from embryonic day (E)16–E18 mouse
embryo cortices until day in vitro 25 (DIV25), when synapses
are known to form in culture. Neurons were cultured in the
presence of the mitotic inhibitor Ara-C (cytosine arabinose),
which limits astrocyte proliferation. The expression of 4E-BP1
decreased significantly by DIV25 in neurons, as compared to
glia, while 4E-BP2 expression remained stable (Figures 1A,
left, and S1A). In addition to the 17-kDa band corresponding
to non-deamidated 4E-BP2, we also observed 2 slower
migrating bands recognized by the 4E-BP2 antibody in SDS-
PAGE from cortical neurons at DIV12 (Figure 1A, left), which
were previously shown to correspond to single and double dea-
midated 4E-BP2 (Bidinosti et al., 2010b; Figure 1A, middle
graphic). To determine whether 4E-BP2 deamidation occurs in
neurons or in glia, we used trypsin to dissociate cells from culture
dishes at DIV10. By re-plating glial cells (passage 1 [p.1]), we
effectively removed all neuronal cells that failed to re-attach.
Following immunoblotting of glial lysates with the 4E-BP2 anti-
body, we detected only non-deamidated 4E-BP2 species
(<17 kDa) (Figure 1A, right), thus revealing that mouse brain-
derived glia express only non-deamidated 4E-BP2, displaying
a faster migration pattern compared to neuronal constitutively
deamidated 4E-BP2. Moreover, treatment with l-phosphatase
did not affect the migration pattern of neuronal DIV25 4E-BP2,rotein Subcellular Localization, but Does Not Alter Its Intrinsically
neurons cultured in the presence of 1 mM Ara-C or glial cells re-plated after
eins; n = 3. Right: representative immunoblots of lysates fromDIV25 neurons or
g control; n = 2. Middle: schematic diagram of the SDS-PAGEmigration pattern
or N102D), and 2D (N99D/N102D). Bottom: schematic of the major domains in
binding site, and Raptor-binding domain (containing the TOS [TOR signaling]
n brain treated with l-phosphatase (l-PPase) (see Table S1); n = 2. For (A) and
E-BP2 on blots. Representative confocal microscopy images at 488 (green) or
ns co-transfectedwithWT (FLAG-tag) and 2D (HA-tag) 4E-BP2 and probed first
ated toWT, green, Alexa Fluor 488; 2D, red, DyLight 680). Scale bars (3 mm) and
ntensity measured images from (C, soma) and (D, dendrites), displaying the
over the green (WT) channel.
highest protein concentration with the average c2 score and normalized spatial
AD E F
B C
Figure 2. Accelerated Proteasomal Degradation and Increased Ubiquitination of Deamidated 4E-BP2
(A–C) Protein stability assays in HEK293H cells transfected with WT or 2D HA-tagged forms of 4E-BP2. Top: representative immunoblots of lysates treated with
(A) cycloheximide 100 mg/mL; 0, 1, and 2 h (CHX); (B) MG132 20 mM; 0 and 6 h; and (C) lactacystin (Lact.) 5 mM; 0 and 6 h, probed with antisera against the
indicated proteins. Bottom: quantification of HA expression normalized against the loading control (b-actin, A and C, or a-tubulin, B) for the indicated time points.
Data are shown as means ± SEMs (error bars); n = 3 per construct. The intensity of the 0-h band is set as 1 (dotted line on graph). Two-way ANOVA; Bonferroni’s
post hoc; *p < 0.05, **p < 0.01.
(D) Top: ubiquitination assay in HEK293H cells. Representative immunoblots from transfected cells with His-ubiquitin and WT or 2D HA-tagged 4E-BP2, treated
with MG132 20 mM for 6 h, from His-immunoprecipitated (IP) or input lysates probed with antisera against the indicated proteins. b-Actin serves as a loading
control. Bottom: quantification of ubiquitination assay data; n = 3, Student’s t test, *p < 0.05.
(legend continued on next page)
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in accordance with previous findings (Bidinosti et al., 2010b), but
it did reduce overall phosphorylation in neurons and in p.1 glia,
as detected by phospho-serine/threonine antisera (Figure 1A,
right). Notably, 4E-BP1 is highly expressed in glia, as compared
to DIV25 neurons (Figures 1A, left, and S1A). Because these ex-
periments were carried out in mouse brain-derived cells, we
sought to identify whether 4E-BP2 deamidation also occurs in
the human brain. Immunoblotting of post-mortem human brain
tissue lysates with the 4E-BP2 antibody showed 2 slower
migrating bands >17 kDa, which are resistant to l-phosphatase
treatment, similar to mouse brain (Figures 1B and S1B). Thus,
these data suggest that 4E-BP2 deamidation is neuron specific
in the mouse brain and also takes place in the adult human brain.
To further study the differences between non-deamidated and
constitutively deamidated 4E-BP2 in neurons, we co-transfected
DIV4 cortical neurons with plasmids expressing N-terminally
tagged non-deamidated (WT; FLAG-tag) and constitutively dea-
midated (2D; hemagglutinin [HA]-tag) 4E-BP2 (Figures 1C and
1D). 4E-BP2 is implicated in cytoplasmic translation initiation,
and using immunofluorescence and confocal microscopy, we
detected punctate WT and 2D staining in the neuronal cell
body and the nucleus (Figure 1C), but also in dendrites in
DIV16 cultured neurons (Figure 1D), which we further validated
by microtubule-associated protein 2 (MAP2) co-staining of
neuronal dendrites (Figure S2A). Whereas no significant differ-
ences were observed in the gross spatial expression of WT
and 2D (apart from a decrease in 2D nuclear staining), there
was very little overlap between the WT and 2D puncta, as
measured by the co-localization of WT and 2D fluorescent sig-
nals, both in soma (r = 0.1464) and in dendrites (r = 0.4019)
(Figure 1E).
Asparagine deamidation may alter protein structure (Robin-
son, 2002). Thus, we set out to determine the structure of deami-
dated 4E-BP2. 4E-BP2 is an IDP (Bah et al., 2015), and because
it lacks ordered 3-dimensional structure, we could not use crys-
tallography. To elucidate WT and 2D structures, we carried out
synchrotron radiation circular dichroism (SRCD), small-angle
X-ray scattering (SAXS), and nuclear magnetic resonance
(NMR) spectroscopy of full-length recombinant 4E-BP2 (WT or
2D) expressed in Escherichia coli and purified in the monomeric
state. First, SRCD spectra forWT and 2D show that both proteins
contain random coils, as evidenced by the negative peak located
near 199 nm (Figure S2B). Second, SAXS scatter profiles for WT
and 2D overlap closely, showing featureless profiles for both
proteins (Figure S2C). Kratky plots for both WT and 2D confirm
their unfolded status (Figure S2D), in accordance with the
SRCD results, suggesting that the protein is flexible and
dominated by random coil structure. The size of WT and 2D pro-
teins appears to depend on concentration (Figure S2E), which
could suggest the presence of a dimer/monomer mixture. The
molecular mass determined for 4E-BP2 using size exclusion(E) Protein stability assays in P56 brain isolated synaptoneurosomes. Representa
Lact. 10 mM; probed with antisera against the indicated proteins. Glyceraldehyd
(F) Quantification of endogenous 4E-BP2 expression in synaptoneurosomes from
bars); n = 3 for all groups apart from lactacystin (n = 5). The intensity of the 0-h ban
0.05. Red arrows mark the slower migration of single or double deamidated 4E-B
See also Figure S4 and Table S2.
3624 Cell Reports 29, 3620–3635, December 10, 2019chromatography-multi-angle light scattering (SEC-MALS) was
15.2 kDa, which is closer to a monomeric state. The ab initio
models generated by DAMMIN and GASBOR fit the experi-
mental SAXS data well and show a similar elongated shape for
both WT and 2D (Figure 1F). Third, NMR spectra show peaks
located in a narrow region, indicative of an IDP (Figure S3). The
majority of the peaks inWT protein spectra overlap with 2D, sug-
gesting that they share a similar structure, with only minor differ-
ences in several residues (Figure S3).
These data reveal that 4E-BP2 deamidation is neuron specific,
occurs in the human brain, affects protein subcellular localiza-
tion, and does not alter the 4E-BP2 IDP state.
Accelerated Proteasomal Degradation and Increased
Ubiquitination of Deamidated 4E-BP2
Since asparagine deamidation may alter protein stability (Robin-
son, 2002), we tested the stability ofWT and 2D 4E-BP2 by trans-
fecting HA-tagged constructs into HEK293H cells. Treatment
with cycloheximide (CHX), an inhibitor of the elongation phase
of protein synthesis, for 1 or 2 h, led to the rapid degradation
of 2D compared to WT at 2 h, as evidenced by HA expression
measured with immunoblotting (Figure 2A). Conversely, inhibi-
tion of the proteasome either with MG132 (Figure 2B) or lacta-
cystin for 6 h (Figure 2C) led to a significant accumulation of
HA-tagged 2D compared to WT (Figures 2B and 2C). Endoge-
nous 4E-BP2 in HEK293H cells or a transfected N99A/N102A
(2A) mutant follow a stability pattern similar to transfected WT
(Figures S4A–S4D). Changes in protein stability due to proteaso-
mal degradation are often preceded by changes in the ubiquiti-
nation status of a protein. Therefore, we used histidine-tagged
ubiquitin (His-Ub) immunoprecipitation in HEK293H cells trans-
fectedwithWT or 2D and immunoblotting to detect ubiquitinated
protein species (Figure 2D). We detected significantly more
HA-2D in His-Ub immunoprecipitates than HA-WT (Figure 2D),
thus demonstrating that the N99D/N102D mutation engenders
increased polyubiquitination, which leads to enhanced protea-
somal degradation.
We then proceeded to examine whether we could recapitulate
the short half-life of 2D in neurons. In lysates from cultured DIV25
cortical neurons treatedwith CHX, lactacystin, orMG132, we de-
tected changes only in 4E-BP2 stability in the MG132-treated
samples (Figure S4E). Inhibition of the proteasome for 9 h with
MG132 led to a significantly higher accumulation of deamidated
(1.5-fold; p = 0.009) compared to non-deamidated 4E-BP2, as
evidenced by the increased intensity of the slower migrating
bands detected by the 4E-BP2 antibody with immunoblotting
(Figure S4E). These data suggest that 4E-BP2 could be more
stable in neurons compared to HEK293H cells. To further test
this hypothesis, we treated neurons with a different elongation
inhibitor, homoharringtonine (HHT); however, we did not observe
any decrease in 4E-BP2 expression after 2 or 9 h (Figure S4E).tive immunoblots of lysates treated for 1 h with HHT 2 mg/mL, MG132 20 mM,
e 3-phosphate dehydrogenase (GAPDH) is the loading control.
(E), normalized to the loading control. Data are shown as means ± SEMs (error
d is set as 1 (dotted line on graph); two-way ANOVA; Bonferroni’s post hoc; *p <
P2 protein.
Dendritic expression of 4E-BP2 (Figures 1C and 1D) led us to
hypothesize that 4E-BP2 stability could be altered in synaptic
fractions. 4E-BP2 (non-deamidated and deamidated) is ex-
pressed in synaptoneurosomal fractions isolated from P56
mouse brain, along with the expression of synaptic proteins
(PSD95, synaptophysin) and the depletion of glial fibrillary acidic
protein (GFAP) and nuclear (histone H3) marker protein (Fig-
ure S4F). In synaptoneurosomes, HHT treatment induced
degradation of deamidated 4E-BP2 significantly more than
non-deamidated (Figures 2E and 2F). Conversely, the treatment
of synaptoneurosomes with MG132 or lactacystin led to a pro-
nounced increase in deamidated compared to non-deamidated
4E-BP2 expression (Figures 2E and 2F). These data suggest that
4E-BP2 deamidation reduces 4E-BP2 stability by increasing 2D
ubiquitination and proteasomal degradation and that this mech-
anism is present in synaptic fractions.
mTOR or Glutamate Receptor Inhibition Promotes
Accumulation of Deamidated 4E-BP2
mTORC1 is amajor signaling pathway regulating translation initi-
ation. mTORC1 activity is significantly downregulated during
early postnatal brain development (postnatal day [P]10–P21),
overlapping with the period when 4E-BP2 deamidation arises
(Figure 3A). Immunoblotting of forebrain lysates prepared from
different ages (E12–P84) reveals a marked decrease in the
phosphorylation of the major downstream translation initiation
effectors of mTORC1 (4E-BP2 and rpS6), concomitant with
an increase in the expression of deamidated 4E-BP2 (Figure 3A).
This result was recapitulated in cerebellar tissue (data not
shown), suggesting that this is a brain-wide phenomenon occur-
ring during early postnatal development and is in accordance
with previous findings (Bidinosti et al., 2010b; Li et al., 2016).
We did not detect this postnatal decrease in mTORC1 signaling
in liver tissue (Figure 3B) or in cultured mouse glia (Fig-
ure S4G), which strongly suggests that this is a neuron-specific
phenomenon.
To establish a causal relation between postnatal decrease in
mTORC1 signaling and the stability of 4E-BP2, we treated
cultured mouse cortical neurons with a selective active-site
mTOR inhibitor, Torin 1 (Thoreen et al., 2009; Figure 3C). Torin
1 treatment led to a significant increase in deamidated protein
amounts compared to non-deamidated at 9 h (Figure 3C) or
48 h (Figures S4H and S4I). The treatment of neurons for the
same duration with the MEK inhibitor U0126 upstream of ERK
(Favata et al., 1998) did not affect the stability of either 4E-BP2
form at 9 h (Figure 3C) or 48 h (Figures S4H and S4I). We did
not detect any changes in 4E-BP2 protein stability in glia
following Torin 1 treatment, further suggesting that this is a
neuron-specific mechanism (Figure S5A). Furthermore, Torin
1-treated synaptoneurosomes analyzed with immunoblotting
reveal a significant increase in deamidated protein expression
compared to non-deamidated (Figure 3D). Likewise, treatment
of synaptoneurosomes with 20 nM rapamycin led to a significant
accumulation of deamidated protein versus non-deamidated
protein (Figure S5B). mTORC1 promotes the activity of the pro-
teasome (Zhao et al., 2015, 2016). Along these lines, in Torin 1 or
rapamycin-treated synaptoneurosomes, we observed a marked
decrease in 20S proteasome activity (Figure S5C).These data suggest that mTORC1 inhibition selectively pro-
motes the neuronal stability of deamidated 4E-BP2 by inhibiting
the activity of the proteasome.
mTORC1 activity is strongly regulated by a-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor (AMPAR) or N-
methyl-D-aspartate receptor (NMDAR) activity (Gong et al.,
2006). Thus, we proceeded to examine whether the inhibition
of AMPARs or NMDARs would affect 4E-BP2 protein stability.
Treating DIV25 neurons with the AMPAR antagonist 2,3-dihy-
droxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX) or the
NMDAR antagonist AP5 for 9 h induced the accumulation of dea-
midated compared to non-deamidated 4E-BP2, similarly to Torin
1 treatment (Figure 3E). Thus, AMPAR or NMDAR inhibition pro-
motes the accumulation of deamidated compared to non-dea-
midated 4E-BP2. This could occur either via inhibiting mTORC1
or by acting directly on the proteasome.
Therefore, these data describe a neuron-specific mechanism
whereby mTORC1 or glutamate receptor inhibition promotes
the accumulation of deamidated 4E-BP2, most likely by inhibit-
ing the activity of the proteasome.
Increased Binding to Raptor and CUL4B Boosts 4E-BP2
Proteasomal Degradation
mTORC1 activation leads to the increased binding of its major
subunit, Raptor, to 4E-BPs (Schalm et al., 2003). We demon-
strated that mTORC1 inhibition, which decreases Raptor-
4E-BP binding, stimulates deamidated 4E-BP2 accumulation
(Figure 3). We thus hypothesized that the increased affinity of
deamidated 4E-BP2 for the mTORC1 protein subunit Raptor (Bi-
dinosti et al., 2010b) could be responsible for enhanced deami-
dated 4E-BP2 proteasomal degradation. To test this hypothesis,
first, we co-transfected HEK293H cells with WT HA-tagged 4E-
BP2 along with a plasmid encoding myc-tagged full-length
Raptor (Figure 4A). CHX treatment for 1 or 2 h led to a significant
decrease (p < 0.01) in the expression of HA-tagged WT 4E-BP2
co-transfected with myc-Raptor, as compared to WT co-trans-
fected with empty vector (Figure 4A). Thus, Raptor co-transfec-
tion reduces the stability of WT 4E-BP2, making it behave
similarly to 2D (Figure 2A). However, myc-Raptor overexpression
dramatically reduced 2D 4E-BP2 expression (70% reduction),
and after 2 h of CHX treatment, the protein does not degrade
further, suggesting that it has reached a plateau (Figure S5D,
red dotted line). Second, if an increase in Raptor binding
(mimicked byRaptor overexpression in this experiment) is causal
for the decreased stability of 2D, then reducing Raptor protein
amounts should reverse this phenotype. Co-transfection of a
small interfering RNA (siRNA) against human RPTOR with HA-
tagged 2D decreases RAPTOR expression and increases the
stability of 2D after 2 h of CHX treatment, as compared to
co-transfection with a scrambled siRNA (Figure 4B). Moreover,
co-transfection of a deletion construct of WT 4E-BP2 lacking
the Raptor-binding domain (WT-DTOS) with myc-Raptor in
HEK293H cells did not alter 4E-BP2-DTOS stability (Figure 4C),
suggesting that 4E-BP2 binding to Raptor is required to induce
protein instability. WT-DTOS degrades faster than full-length
WT 4E-BP2, most likely because of its shorter length. Likewise,
2D-DTOS degrades faster than full-length 2D, but WT-DTOS
and 2D-DTOS have similar degradation rates (Figure S5E). Third,Cell Reports 29, 3620–3635, December 10, 2019 3625
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Figure 3. mTOR, AMPAR, or NMDAR Inhibition Promotes the Accumulation of Deamidated 4E-BP2
(A) mTORC1 and 4E-BP2 deamidation in the brain. Immunoblotting of mouse forebrain lysates collected at different ages and probed with antisera against the
indicated proteins.
(B) mTORC1 and 4E-BP2 deamidation in the brain versus the liver.
(C) Top left: diagrammatic depiction of pathways inhibited by Torin 1 and U0126 inhibitors. Bottom left: representative immunoblots from DIV25 neuron lysates
treated with vehicle or 250 nM Torin 1, or vehicle or 20 mM U0126 for 9 h, probed with antisera against the indicated proteins; Hsc70 is a loading control. Right:
quantification of immunoblots; 4E-BP2 expression normalized to control is shown for WT and deamidated (2D) 4E-BP2.
(D) Top: representative immunoblots from P56 mouse brain-extracted synaptoneurosomes treated with vehicle or 250 nM Torin 1 for 1 h, probed with antisera
against the indicated proteins. Bottom: quantification of immunoblots; 4E-BP2 expression normalized to control is shown for WT and deamidated (2D) 4E-BP2.
(E) Representative immunoblots (left) and quantification of 4E-BP2 expression normalized to control (right) from DIV25 neuron lysates treated with vehicle, 10 mM
NBQX, or 50 mM AP5 for 9 h, probed with antisera against the indicated proteins. GAPDH is the loading control.
For (A) and (B), the blue arrows show the phosphorylation of 4E-BP2, while the red arrows mark the slower migrating forms of deamidated (single or double)
4E-BP2 protein.
For (C)–(E), the data are shown asmeans ±SEMs (error bars). For (C) and (E), n = 3 per condition. For (D), n = 5 per condition. The intensity of the vehicle band is set
as 1 (dotted line on graph). Two-way ANOVA; Bonferroni’s post hoc; *p < 0.05, **p < 0.01.
See also Figures S4 and S5 and Table S2.
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to identify the underlying mechanism by which Raptor facilitates
increased proteasomal degradation of 2D, we examined a ubiq-
uitin E3 ligase complex comprising CUL4B and DNA damage-
binding protein 1 (DDB1), because this complex binds Raptor
(Ghosh et al., 2008). We co-transfected HEK293H cells with
myc-Raptor and HA-tagged WT or 2D and processed lysates
with myc immunoprecipitation to isolate Raptor-bound proteins
(Figure 4D). By subjecting immunoprecipitates to immunoblot-
ting, we detected significantly more HA-tagged 2D bound to
myc-Raptor, as compared to HA-tagged WT (Figure 4E). Further
probing of these samples with CUL4B and DDB1 antisera re-
vealed increased binding of CUL4B to myc-Raptor in the pres-
ence of 2D, when compared to WT (Figures 4D and 4E). DDB1
binding was not changed between WT and 2D samples, which
is in accordance with Ghosh et al. (2008). We did not observe
any differences in the protein expression of myc-Raptor,
CUL4B, or DDB1betweenWTand 2D in input lysates (Figure 4D).
To further elucidate the connection of CUL4B to 2D 4E-BP2 sta-
bility, we knocked down endogenous CUL4B in HEK cells using
siRNAs and measured the stability of co-transfected HA-tagged
2D 4E-BP2 (Figure S5F). We observed that the reduced expres-
sion of endogenousCUL4Bcorrelateswith the increased stability
of 2D following CHX treatment (Figure S5D). In addition,
recombinant 2D is significantly more ubiquitinated in a CUL4B-
dependent in vitro ubiquitination assay, as compared to WT
(Figures 4F, 4G, andS5G). In conclusion, thesedata strongly sug-
gest that the decreased stability of deamidated 4E-BP2 is medi-
ated by increased binding to the Raptor-CUL4B-DDB1 complex.
Overexpression of Deamidated 4E-BP2 Alters the
Neuronal Translational Landscape and Regulates NF-kB
Activity
Deamidation of 4E-BP2 during early postnatal brain develop-
ment could constitute a translational control mechanism target-
ing repression of a distinct pool of mRNAs. To mimic conditions
in which 2D is more abundant due to accumulation, such as
following mTORC1 or AMPAR or NMDAR inhibition, we overex-
pressed 2D in neurons. Tomap the 2D-regulated translatome, as
compared to WT, we carried out unbiased translational profiling
using ribosome footprinting coupledwith RNA sequencing (Ingo-
lia et al., 2012). DIV10 mouse cortical neurons were infected with
adeno-associated virus serotype 9 (AAV9) expressing FLAG-
tagged WT or 2D 4E-BP2, driven by the neuron-specific humanFigure 4. Increased Binding to Raptor and CUL4B Boosts 4E-BP2 Prot
(A–C) Top: representative immunoblots from HEK293H lysates co-transfected wi
co-transfected with siRNA (scrambled or against RAPTOR) and 2D HA-tagged 4E
DTOS. Bottom: quantification of HA expression (corresponding to WT or 2D) mea
4E-BP2 domains is shown to highlight the C-terminal deletion of the TOS motif (
(D) Representative immunoblots fromHEK293H immunoprecipitates (IP; top, with
and WT or 2D HA-tagged 4E-BP2 and probed with the antisera against the indi
expression in IP. Right: depiction of the Raptor-CUL4B-DDB1-2D complex.
(E) Quantification of data in (D) for HA expression and CUL4B bound to myc-Rap
(F) In vitro ubiquitination assay of purified GST-4E-BP2WT or 2D. The reactions w
UBE2L3, and UBE1 proteins and probed with the antisera against the indicated
(G) Quantification of ubiquitination data in (E); Student’s t test (n = 3); *p < 0.05.
For (A)–(C), all of the experiments were carried out in the presence of 100 mg/mL c
shown as means ± SEMs (error bars); n = 3 per condition; two-way ANOVA; Bon
See also Figure S5 and Table S2.
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neuronal lysates at DIV25 revealed the robust expression of
WT and 2D, detected by anti-FLAG antisera (Figure 5A, left). Us-
ing a hypotonic lysis buffer, we first extracted polysomes and
subsequently isolated ribosome-protected footprints following
RNase I nuclease digestion. In parallel, we isolated total RNA
from neuronal culture lysates. From both ribosome-protected
footprints (a proxy for translation) and total mRNA (a proxy for
transcription), we prepared libraries for RNA sequencing (Fig-
ure 5A, right). NovaSeq (Illumina) produced high-quality reads
for footprint and mRNA libraries, as evidenced first by the r2 of
reads per kilobase of transcript per million mapped reads
(RPKM) between biological replicates, which is >0.9 for both
footprints and total mRNA (Figure S6A), second by the canonical
distribution of footprint size (28–32 nt) (Figure S6B), third by the
read distribution within the 3 frames (Figure S6C), and fourth
by the canonical periodicity of ribosomal footprints across
mRNA coding and non-coding regions (Figure S6D). RPKM
measurements of mRNA libraries demonstrate that there is no
significant change in mRNA abundance between WT and 2D
as evidenced by R2 = 0.972, suggesting that there are no major
differences in transcriptional responses (Figure 5B). Conversely,
RPKM reads of footprints normalized to mRNA abundance
(translational efficiency [TE]) show a pervasive change in the
translational landscapes of WT versus 2D 4E-BP2 (R2 = 0.681)
(Figure 5C). Analysis of log2 of TE between 2D andWT replicates
(ratio <0.667 and ratio >1.5, respectively; p < 0.05) indicated that
212 genes were upregulated (repressed by WT overexpression),
while 238 genes were downregulated (repressed by 2D overex-
pression), revealing 2 highly dissimilar translatomes (differen-
tially translated genes [DTGs]) for WT and 2D (Figure 5C; Table
S3). To elucidate the features of mRNAs, which could render
them sensitive to either WT or 2D 4E-BP2 regulation during
translation initiation, we obtained 50 UTR sequences for both lists
of targets and carried out length, guanine-cytosine (GC) content,
andmotif analyses using UTRdb (Grillo et al., 2010). 2D-sensitive
mRNA 50 UTRs were shorter and harbored significantly lfewer
terminal oligopyrimidine tract (TOP) and upstream open reading
frame (uORF) elements, as compared to WT-sensitive mRNA 50
UTRs, while %GC content was not different (Figure 5D).
Furthermore, to identify pathways affected by 2D-sensitive
mRNAs, we carried out Gene Ontology (GO) analysis using
DAVID (Figure 5E; Table S4). Multiple GO categories linked toeasomal Degradation
th myc-Raptor (A). WT HA-tagged 4E-BP2 and empty vector or myc-raptor (B)
-BP2, or (C) HA-4E-BP2 DTOS with empty vector or myc-Raptor + HA-4E-BP2
sured by immunoblotting, normalized to b-actin. In (C, bottom), a depiction of
DTOS).
anti-myc antisera) andwhole lysates (bottom), co-transfected with myc-Raptor
cated proteins; b-actin is the loading control. The red arrow shows increased
tor, Student’s t test (n = 2),*p < 0.05.
ere performed in the presence of purified CUL4B, Raptor, DDB1, His-ubiquitin,
proteins. GST, glutathione S-transferase.
ycloheximide (CHX) for 0, 1, or 2 h; b-actin is the loading control. The data are
ferroni’s post hoc; **p < 0.01, **p < 0.001.
A B
C D
E
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transcription (p < 0.05; biological pathways [BP], molecular func-
tion [MF], and cellular compartment [CC]), were identified by
DAVID analysis of the 212 WT-repressed genes, suggesting
that the overexpression ofWT4E-BP2 could elicit the homeostat-
ic modulation of transcription (Figure 5E, left). In contrast, 2D-
repressed genes displayed a DAVID GO profile that was distinct
from WT, including categories such as MF: poly(A) RNA binding,
NF-k binding; BP: cerebral cortex development, NF-kB activity,
glutathione metabolic process, and oxidoreductase activity;
and CC: mitochondrion (Figure 5E, right). Moreover, when we
carried out ingenuity pathway analysis (IPA) of DTGs using the
molecular activity predictor (MAP) tool, we identified networks
predicted to be regulated by WT and 2D 4E-BP2 (Figure 6A).
The top network is developmental disorder, hereditary disorder,
and neurological disease (comprising 21 2D-sensitive genes
and 12 WT-sensitive genes), with the central node being NF-kB
(Figure 6A). This predicted network suggests that the balance
of WT-2D 4E-BP2 is important for regulating NF-kB activity. In
summary, deamidated 4E-BP2 represses the translation of a
subset of mRNAs, which is distinct from WT 4E-BP2-regulated
mRNAs and seems to play a pivotal role in the regulation of NF-
kB activity. To test this hypothesis, which originated from our un-
biased translatome profiling, we used an NF-kB activity reporter
in a stable HEK293 cell line, with a luciferase-based system as a
readout (Figure 6B). The overexpression of 2D 4E-BP2 represses
both basal and tumor necrosis factor a (TNF-a)-stimulatedNF-kB
activity, while WT only represses TNF-a-stimulated NF-kB activ-
ity (Figure 6B). 2D repression of NF-kB activity following TNFa
stimulation is significantly higher when compared to WT (Fig-
ure 6B), in agreement with the IPA network prediction (Figure 6A).
Thus, postnatal brain-specific reduction in mTORC1 signaling
could regulate brain NF-kB activity by inhibiting proteasome ac-
tivity and subsequently leading to the accumulation of deami-
dated 4E-BP2 (Figure 6C).
DISCUSSION
We describe a previously unidentified mechanism during early
postnatal brain development whereby the deamidated form of
the cardinal brain translation initiation repressor 4E-BP2 is
more susceptible to ubiquitin proteasomal degradation (as
compared to non-deamidated protein) because it binds with
higher affinity to a complex comprising the mTORC1 protein
Raptor and the ubiquitin E3 ligase CUL4B. Deamidated 4E-
BP2 stability is regulated by mTORC1 and glutamate receptor
activity. The overexpression of deamidated 4E-BP2 repressesFigure 5. Overexpression of Deamidated 4E-BP2 Alters the Neuronal T
(A) Left: overexpression of FLAG-tagged 4E-BP2 (WT or 2D) using AAV9. Repre
DIV10. GAPDH is a loading control. Right: diagrammatic depiction of the ribosom
(B) Scatterplot and correlation of RPKM measured from WT or 2D mRNA from DI
(C) Scatterplot and correlation of translational efficiency (footprint RPKM normaliz
RPKM of 2D versus WT). Differentially translated genes (DTGs), repressed by WT
(D) 50 UTR analysis of DTGs versus mouse 50 UTR collection: length (nt), %GC co
GC: one-way ANOVA; Bonferroni’s post hoc; ***p < 0.001; # change in motif abu
(E) DAVID analysis of DTGs (WT left, orange; 2D right, blue) for Gene Ontology (GO
genes in each category is shown and the order of categories is by decreasing p va
discussed further in the text.
See also Figure S6 and Tables S3 and S4.
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development, mitochondria, and chiefly NF-kB activity.
4E-BP2 deamidation occurs in mouse neurons, but not in glial
cells (Figure 1A). Deamidated 4E-BP2 is only detected in post-
natal and adult brains, and not in the other peripheral tissues
examined (Bidinosti et al., 2010b). Thus, our data support a
neuron-centric role for 4E-BP2 deamidation during early post-
natal development and into adulthood. Deamidated 4E-BP2 is
also present in the human brain (Figure 1B). Potentially, this
mechanism is evolutionary conserved from rodents to humans
to preferentially regulate neuronal translation during a crucial
developmental period for brain growth, synapse regulation,
neuronal proliferation and migration, and ultimately, circuitry for-
mation and behavior (Semple et al., 2013; Pressler and Auvin,
2013). The period when deamidation arises (P10–P21) in mice
(concomitant with a decrease in mTORC1 activity) would corre-
spond to 10 months–3 years of age in human children (Semple
et al., 2013). mTORC1 activity is dysregulated in several mono-
genic disorders co-diagnosed with high rates of autism, such
as fragile X syndrome and tuberous sclerosis (Kelleher and
Bear, 2008). Global knockout of 4E-BP2 engenders molecular,
cellular, and behavioral phenotypes, which are reminiscent of
ASDs (Gkogkas et al., 2013). Other studies have described a
key role for 4E-BP2 in synaptic function, learning, and memory
(Banko et al., 2005, 2006, 2007; Ran et al., 2013). Given these
studies and our work, it is conceivable that dysregulated deami-
dated 4E-BP2 degradation, as a result of altered mTORC1
signaling during development, could be linked to a prodromal
period of neurodevelopmental disorders such as ASDs (via aber-
rant translational control of neuronal mRNAs).
Postnatal brain-specific asparagine deamidation of 4E-BP2
(N99D/N102D) is spontaneous and pH dependent, and there is
no current evidence that it is catalyzed by enzymes (Bidinosti
et al., 2010b; Robinson, 2002). However unlikely it may be, an
as yet unidentified protein complex or enzyme could carry out
4E-BP2 deamidation, similarly to RIG-I (He et al., 2015), which
regulates antiviral cytokine production, or to the immune sensor
cGAS (Zhang et al., 2018). Furthermore, the pronounced slower
migration of deamidation-corresponding bands on SDS-PAGE
suggests that deamidation may affect 4E-BP2 structure (Fig-
ure 1). Moreover, mTORC1 phosphorylation induces folding of
the intrinsically disordered 4E-BP2 protein (Bah et al., 2015).
We did not detect major changes in deamidated 4E-BP2 struc-
ture by SAXS, SRCD, or NMR, as compared to WT (Figures 1,
S2, and S3); both proteins are IDPs comprising random coils.
Structural analysis of deamidated 4E-BP2 in complex withranslational Landscape
sentative immunoblots from DIV25 mouse cortical neuron lysates, infected at
e profiling experiment.
V25 neurons, as a proxy for transcription, from DIV25 overexpressing neurons.
ed to mRNA RPKM) between WT and 2D overexpressing DIV25 neurons (log2
(orange) or 2D (blue), are shown for 0.667 < ratio > 1.5.
ntent, and UTRdb motifs. Data are shown as means ± SEMs. For length and%
ndance.
) categories molecular function, biological processes, and CC. The number of
lue (see Table S3; all p values shown here are <0.05). The categories in bold are
(legend on next page)
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Raptor or eIF4E could reveal undetected conformational
changes in its IDP state. WT and 2D subcellular localization
was similar, but there was little overlap between the fluorescent
puncta corresponding to each form (Figures 1C–1E).
At the same time, for many proteins, deamidation is tradition-
ally viewed as an ‘‘aging by-product,’’ which labels long-lived
proteins for degradation (Robinson, 2002). In accordance with
this, we do find that 2D is more ubiquitinated and less stable
than WT 4E-BP2 (Figure 2). Only the deamidated form and not
an alanine mutant (2A) exhibited reduced protein stability, sug-
gesting that this phenotype is specifically induced by the conver-
sion of asparagines to aspartates and not by a non-specific
mutation. We then show that 2D stability can be regulated by a
major signaling pathway (mTOR) and the activity of glutamate re-
ceptors (Figure 3), and that 2D overexpression engenders a
widespread alteration of the neuronal translatome (Figure 5),
thus demonstrating that 4E-BP2 deamidation is highly regulated
by major neuronal signaling pathways and receptor activity, and
that it plays a key functional role. The lower stability of 2D,
together with the non-overlapping puncta of WT and 2D de-
tected in dendrites (Figure 1D), support the hypothesis that the
two forms of 4E-BP2 may regulate the function of different types
of synapses, by selective translational de-repression of different
mRNAs. In accordance with this premise, 2D was shown to pref-
erentially regulate excitatory AMPA synaptic transmission (Bidi-
nosti et al., 2010b).
Deamidated 4E-BP2 is degraded by binding with higher affin-
ity to the mTORC1 protein Raptor and the ubiquitin E3 ligase
CUL4B (Figure 4), while pharmacological inhibition of mTORC1
promotes deamidated 4E-BP2 accumulation (Figure 3) and re-
duces Raptor-4E-BP2 binding (Schalm et al., 2003). These
data reveal that there is a causal relation between Raptor-deami-
dated 4E-BP2 binding and protein stability under the control of
mTORC1 activity. It is plausible that accelerated 2D 4E-BP2
degradation (through the formation of the Raptor-2D-CUL4B
complex) could be part of a wider brain-specific mechanism
involving CUL4B and the proteasome, mediating translational
de-repression downstream of mTORC1 in certain synapses.
Regulation of such synapses could be pivotal for the pathogen-
esis of ASDs and other neurodevelopmental disorders, in which
there are known changes inmTORC1 activity (Costa-Mattioli and
Monteggia, 2013; Huber et al., 2015; Kelleher and Bear, 2008).
We were unable to recapitulate this mechanism for endogenous
proteins due to technical challenges with the immunoprecipita-
tion of Raptor or 4E-BP2 in brain tissue and because of the
lack of a 4E-BP2 deamidation-specific antibody.
Furthermore, CUL4B is an X-linked intellectual disability
(XLID)-associated gene, and its deletion in mice leads to embry-
onic lethality (Chen et al., 2012; Jiang et al., 2012). In addition,
CUL4B overexpression increases ubiquitination and proteaso-
mal degradation of tuberous sclerosis 2 protein (TSC2; anFigure 6. 4E-BP2-Mediated Translational Control Regulates NF-kB Ac
(A) Left: IPA of ribosome-profiling DTGs from Figure 5 with the molecular activity
detailed node graph of the top scoring network—developmental disorder, hered
Direct and indirect relations between nodes are shown for DTGs repressed by W
(B) NF-kB reporter assay in HEK293 cells using a luciferase-based assay. Two-w
(C) Diagrammatic summary of the mechanism described in this paper.
3632 Cell Reports 29, 3620–3635, December 10, 2019inhibitor of mTORC1 and syndromic ASD gene; Short et al.,
1995) and thus promotes mTORC1 signaling (Ghosh et al.,
2008). XLID-linked truncating or missense mutations in CUL4B
were shown to be defective in promoting the degradation of
TSC2 (Wang et al., 2013). Notably, a link between 4E-BP1 and
CUL3 was previously shown to promote hypo-phosphorylated
4E-BP1 ubiquitination and degradation, while hyper-phosphory-
lated 4E-BP1 is refractory to degradation (Yanagiya et al., 2012).
Nevertheless, 4E-BP1 is highly expressed in glial cells, while 4E-
BP2 (both deamidated and non-deamidated) is predominantly
expressed in neurons (Figure 1A), suggesting a potential dichot-
omy between CUL4B-CUL3 mechanisms in neurons and glia.
Ribosome profiling data highlighted the aspects of a wider
brain-specific mechanism involving 4E-BP2 deamidation (Fig-
ure 5). The overexpression of 4E-BP2 forms was carried out us-
ing AAV constructs driven by hSyn promoters in a culture that is
predominantly neuronal (>90% of cells) (Davis and Temple,
1994), while we also demonstrated that deamidation arises in
neurons, but not in glia (Figure 1). However, we cannot exclude
the possibility that the translational changes detected may be
due to a non-neuron autonomous effect on glial cells. Cell-
type-specific ‘‘translatomics’’ (e.g., translating ribosome affinity
purification [TRAP]; Heiman et al., 2014) would be required to
answer this question. We detected a low correlation between
the changes in the translatome following overexpression of the
two 4E-BP2 forms and no significant changes in transcription
(Figures 5B and 5C). Using UTRscan of DTGs, we discovered
that WT but not 2D DTGs are enriched in 50 UTR features previ-
ously reported in mTOR- and eIF4E-sensitive mRNAs (Hsieh
et al., 2012; Mamane et al., 2007; Thoreen et al., 2012; Truitt
et al., 2015) and could result from the reduced binding of 2D to
eIF4E (Bidinosti et al., 2010b) and/or from the increased sensi-
tivity of 2D tomTOR inhibition (Figure 3). Consequently, GO func-
tional analysis showed a very small overlap between WT-2D
translatomes, revealing that WT overexpression predominantly
elicits widespread translational changes in genes involved in
transcription, which could constitute a homeostatic response
(Figure 5). Conversely, 2D-regulated genes are involved in cere-
bral cortex development and NF-kB activity (Figure 5).
A main avenue for NF-kB activity regulation perinatally in brain
is through de-repression, following phosphorylation of its inhibi-
tor IkBa (nuclear factor of k light-chain polypeptide gene
enhancer in B cells a). Thismechanism is brain-derived neurotro-
phic factor (BDNF) dependent prenatally and BDNF independent
postnatally (Gutierrez and Davies, 2011; Gavalda` et al., 2009).
Moreover, the top GO CC detected by DAVID in 2D regulated
genes is the mitochondrion (Figure 5E). 4E-BPs were shown to
regulate mitochondrial dynamics and biogenesis by the transla-
tional control of nucleus-encoded mitochondria-related mRNAs
(Morita et al., 2013, 2017). We identified 35 mitochondrial
mRNAs in 2D-regulated DTGs (Table S3). Remarkably, thetivity
predictor (MAP) analysis tool. The top five scoring networks are shown. Right:
itary disorder, and neurological disease—in which NF-kB is the central node.
T (red) or 2D (green) within the predicted network.
ay ANOVA with Bonferroni’s post hoc; ***p < 0.001, n = 6 for each group.
highest scoring network predicted by IPA is developmental dis-
order, hereditary disorder, neurological disease, and NF-kB is
the central node (Figure 6A), while we demonstrated that 2D is
a stronger inhibitor of NF-kB activity than WT (Figure 6B). It
was suggested that synaptic activity promotes a neuronal War-
burg effect, shifting neuronal energy metabolism from oxidative
phosphorylation toward aerobic glycolysis (Bas-Orth et al.,
2017). In parallel, mitochondrial gene expression peaks during
synaptogenesis (P0–P21) (Wirtz and Schuelke, 2011). Further-
more, the interplay between NF-kB and the tumor suppressor
p53 was proposed to underlie the metabolic switch of the
Warburg effect by regulating nuclear and mitochondrial gene
expression (Johnson and Perkins, 2012). 4E-BPs were shown
to regulate senescence by controlling the synthesis of the p53-
stabilizing protein Gas2 (Petroulakis et al., 2009).
Our ribosome profiling data and the existing evidence
regarding NF-kB activity and mitochondria emphasize the
importance of our proposed brain-specific translational control
mechanism of mTORC1- or glutamate receptor-mediated,
Raptor-dependent proteasomal degradation of deamidated
4E-BP2 during a critical period of postnatal brain development
(Figure 6C), which could go awry in neurodevelopmental disor-
ders such as ASDs.STAR+METHODS
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Antibodies
4E-BP2 Cell Signaling Technologies 2845S
4E-BP1 (53H11) Cell Signaling Technologies 9644S
Phospho-4E-BP1 (Thr37/46) (236B4) Cell Signaling Technologies 2855S
Phospho-S6 Ribosomal Protein (Ser240/244) Cell Signaling Technologies 2215S
Ribosomal Protein S6 Antibody (C-8) Santa Cruz Biotechnology sc-74459
c-Myc Antibody (9E10) Santa Cruz Biotechnology sc-40
Anti-Cullin 4B antibody Abcam ab67035
DDB-1 Cell Signaling Technologies 5428S
HA Tag Monoclonal Antibody (2-2.2.14), DyLight 680 ThermoFisher Scientific 26183-D680
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling Technologies 7074S
HSC 70 Antibody (B-6) Santa Cruz Biotechnology sc-7298
DYKDDDDK Tag Monoclonal Antibody (L5), Alexa Fluor 488 ThermoFisher Scientific MA1-142-A488
Anti-mouse IgG, HRP-linked Antibody #7076 Cell Signaling Technologies 7076S
p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb Cell Signaling Technologies 4695S
GAPDH (14C10) Rabbit mAb Cell Signaling Technologies 2118S
Monoclonal Anti-b-Actin antibody produced in mouse Merck A5316-100UL
Monoclonal ANTI-FLAG M2 antibody produced in mouse Merck F1804-200UG
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Antibody Cell Signaling Technologies 9101S
Anti-mouse IgG for IP (HRP) Abcam ab131368
Ubiquitin Cell Signaling Technologies 3933S
a-Tubulin Sigma-Aldrich T9026
Phospho-Threonine-Proline Cell Signaling Technologies 9391S
Anti-HA.11 Epitope Tag (Formerly Covance MMS-101R-500) Cambridge Bioscience 901514
PSD95 (D27E11) XP Rabbit mAb Cell Signaling Technologies 3450S
Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) antibody
produced in mouse - 100UL
Merck G3893-100UL
Histone H3 (D1H2) Cell Signaling Technologies 12648S
Synaptophysin - 1 Synaptic Systems 101 011
Raptor (24C12) Rabbit mAb Cell Signaling Technologies 2280S
His-Tag Antibody Cell Signaling Technologies 2365S
UBE2L3 Antibody Cell Signaling Technologies 3848S
MAP2 antibody Sigma M9942
Chemicals
TNFa Sigma T0157
Cycloheximide Merck C7698-1G
Lactacystine Merck L6785-.2MG
MG132 (Z-Leu-Leu-Leu-al) Merck C2211-5MG
Homoharringtonine Merck SML1091-10MG
Torin1 Tocris Bioscience 4247
Rapamycin LC Laboratories R5000-100MG
U0126 Tocris Bioscience 1144
Betullinic acid Merck B8936
NBQX Abcam ab120046
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D-AP5 HelloBio HB0225
Proteasome Substrate III, Fluorogenic, Suc-Leu-Leu-Val-
Tyr-AMC
Calbiochem 539142-5MG
Critical Commercial Assays
Dual-Luciferase Reporter Assay System Promega E1910
TriFECTa DsiRNA Kit for hs.Ri.RPTOR.13 IDT N/A
TriFECTa DsiRNA Kit for hs.Ri.CUL4B.13 IDT N/A
Clarity Western ECL Substrate Biorad 1705061
Pierce ECL Western Blotting Substrate ThermoFisher Scientific 32106
TruSeq Ribo Profile (Mammalian) Kit Illumina RPHRM12126
Ribo-Zero Gold (Human/Mouse/Rat) Kit Illumina MRZG126
Agilent Small RNA Kit Agilent Technologies 5067-1549
NEXTflex Small RNA Sequencing Kit v3 Bioo Scientific NOVA-5132-06
NF-kB reporter (Luc) - HEK293 Recombinant Cell line BPS Bioscience 60650
Experimental models: Cell Lines
Human Embryonic Kidney cells (HEK293H ATCC CRL-1573 ThermoFisher Scientific 11631017
Recombinant DNA
pCDNA3-3HA–4E-BP2 WT Bidinosti et al., 2010b N/A
pCDNA3-3HA–4E-BP2 N99D/N102D Bidinosti et al., 2010b N/A
pCDNA3-3HA–4E-BP2 DTOS Bidinosti et al., 2010b N/A
pCDNA3-3HA–4E-BP2 N99D/N102D DTOS This paper N/A
pCDNA3-3HA–4E-BP2 N99A/N102A Bidinosti et al., 2010b N/A
pGEX-6P-1-4E–BP2 WT Bidinosti et al., 2010b N/A
pGEX-6P-1-4E–BP2 N99D/N102D Bidinosti et al., 2010b N/A
Myc-Raptor Addgene and PMID: 15268862 Cat#: 1859 (discontinued)
AAV9-hSyn1-3XFlag-4E-BP2 WT-IRES-GFP-WPRE Vector Biolabs N/A
AAV9-hSyn1-3XFlag-4E-BP2 N99D/N102D-IRES-GFP-WPRE Vector Biolabs N/A
His-Ubiquitin (Hock et al., 2011) N/A
pTK-RL (Gkogkas et al., 2008) N/A
Software and Algorithms
Adobe Illustrator Adobe https://www.adobe.com/creativecloud.html
GraphPad PRISM Graphpad https://www.graphpad.com/scientific-
software/prism/
Fiji ImageJ software Open source https://fiji.sc/
Imaris software Bitplane https://imaris.oxinst.com/
NIS-Elements-v4.13 software Nikon https://www.microscope.healthcare.nikon.
com/en_EU
Huygens Software 4.5.1p3 Scientific Volume Imaging https://svi.nl/HuygensSoftware
ImageStudio Software LI-COR https://www.licor.com
ATSAS software suite (Konarev et al., 2003) https://www.embl-hamburg.de/biosaxs/
software.html
DAMMIN (Svergun, 1999) https://www.embl-hamburg.de/biosaxs/
dammin.html
GASBOR (Svergun et al., 2001) https://www.embl-hamburg.de/biosaxs/
gasbor.html
Multifastats GITHUB opensource code https://github.com/davidrequena/multifastats
UTRdb/UTRscan (Grillo et al., 2010). (Grillo et al., 2010).
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Ingenuity Pathway Analysis (IPA) QIAGEN https://www.qiagenbioinformatics.com/
products/ingenuity-pathway-analysis/
Database for Annotation, Visualization and Integrated
Discovery (DAVID)
(Huang et al., 2009) https://david.ncifcrf.gov/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and unique/stable reagents should be directed to andwill be fulfilled by the LeadCon-
tact, Christos G. Gkogkas (christos.gkogkas@ed.ac.uk.) with a completed Materials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All procedures were in accordancewith UKHomeOffice andCanadian Council on Animal Care regulations andwere approved by the
University of Edinburgh andMcGill University. C57BL/6J background animals were used (backcrossed for more than 10 generations;
pregnant dams to collect E16-18 embryos and P56 males). Food and water were provided ad libitum, and mice were kept on a 12 h
light/dark cycle. Pupswere kept with their dams until weaning at postnatal day 21. After weaning,micewere group housed (maximum
of 6 per cage) by sex. Cages weremaintained in ventilated racks in temperature (20-21C) and humidity (55%) controlled rooms, on
a 12-hour circadian cycle (7am-7pm light period).
Human tissue
Post – mortem human brains were acquired from the MRC Edinburgh Brain & Tissue Bank.
See Table S1
Cell line cultures
All cell culture reagents were from ThermoFisher Scientific. Human Embryonic Kidney cells (HEK293H ATCC CRL-1573) were
cultured (37C, 5% CO2) in Dulbecco’s modified Eagle’s medium (DMEM, 11995065) containing 10% fetal bovine serum
(10500064) and 1% Pen/Strep (15140148).
Primary dissociated cortical neuronal cultures
All reagents for cell culture were from ThermoFisher Scientific unless stated otherwise. E16-18 mouse embryos (male and female)
were collected from pregnant dams and cortices were dissected from the brain and immersed in ice cold HBSS solution
(14170146) supplemented with 1x Antibiotic/antimycotic mix (15240062) and HEPES solution at concentration 10 mM (15630106).
Cells were dissociated after addition of 1 mg/ml Trypsin (LS003702, Lorne Laboratories) and incubation for 15 min at 37C. Then,
0.05mg/ml Dnase I (D5025-15KU,Merck) was added and the cells were incubated for 5min at 37C. After the incubation, Neurobasal
media (21103049) was added twice, supplemented with 1x Antibiotic/antimycotic mix, 1x Glutamax (35050038), B-27 (17504044)
and 10% Horse Serum (26050088) to inhibit Trypsin. Then, DNase I was added again and the tissue was triturated. The cells
were plated on dishes that were coated with 0.05 mg/ml Poly-D-Lysine (P7886, Merck) for 2 h the day before tissue dissection.
5 h after plating, the media was removed and replaced by new media without serum. Half of the media was replaced every
3 days, supplemented with 1 mM Cytosine b–D–arabinofuranoside hydrochloride (Ara-C, C6645-25MG, Merck). To obtain glial cul-
tures, Ara-C-free DIV10 neuronal cultures were trypsinised with Trypsin-EDTA (25300054). Cells were washed twice in 1x PBS and
replated in DMEM (11995065) supplemented with 10% fetal bovine serum (10500064) and 1% Pen/Strep (15140148).
METHOD DETAILS
Transfection of cell-lines or primary neurons and reagents
Transfection of HEK293H cells or primary neurons was carried out with Lipofectamine 3000 (L3000008, Thermo Fisher Scientific) in
Opti-MEM (31985070, ThermoFisher Scientific) following the manufacturer’s protocol.
Protein stability assay
HEK293H cells were transfectedwith 1-2 mgDNA (or 10 nM siRNA). Pilot experiments were carried out to calculate the required mg for
each plasmid construct to ensure equal starting amounts of protein. For protein stability assays, after 48 h, transfected HEK293H
cells, (non-transfected cultured neurons or isolated synaptoneurosomes) were treated with 100 mg/ml Cycloheximide (C7698-1G,
Merck), 5 mM or 10 mM Lactacystine (L6785-.2MG, Merck), 20 mM MG132 (Z-Leu-Leu-Leu-al, C2211-5MG, Merck), 2 mg/ml HHTe3 Cell Reports 29, 3620–3635.e1–e7, December 10, 2019
(SML1091-10MG, Merck), 250 nM Torin 1 (4247, Tocris Bioscience), 20 nM Rapamycin (R5000-100MG), 20 mMU0126 (1144, Tocris
Bioscience), 2.5 mg/ml Betullinic acid (B8936, Merck), 10 mMNBQX (ab120046, Abcam) and 50 mMD-AP5 (HBO225, HelloBio) for the
indicated period of time.
Adenoassociated viruses (AAV) and infection of cortical cultures
All AAVs were purchased from Vector Biolabs. AAV vectors were cloned by Vector Biolabs: AAV9-hSyn1-3Xflag-4E-BP2 WT-IRES-
GFP-WPRE and AAV9-hSyn1-3Xflag-4E-BP2 N99D/N102D-IRES-GFP-WPRE and were used to generate3.5x1013 GC/ml for each
AAV. Primary dissociated cortical neuronal cultures were infected at DIV10 with 7x1011 GC/ml of each virus and collected at DIV25.
In vivo ubiquitination assay
HEK293H cells were transfected with 5-10 mg of 3xHA-plasmids expressing either WT or 2D 4E-BP2 (pilot experiments were carried
out to determine the required amount (mg) for each plasmid construct to ensure equal starting amounts of protein) and 10 mg His-
Ubiquitin (Hock et al., 2011). After 48 h of transfection, cells were treated with 20 mM MG132 for 6 h. Cells were lysed in urea buffer
(8 M Urea, 0.1 M NaH2PO4, 0.1 M Tris-HCl [pH 8.0], 0.05% Tween 20, and 10 mM imidazole [pH 8.0]). 5 mg of total protein was incu-
batedwith Ni-NTAAgarose beads (30210, QIAGEN) overnight to pull down ubiquitinated proteins. The beadswerewashed twicewith
denaturing wash buffer (8MUrea, 0.1MNaH2PO4, 0.1M Tris-HCl [pH 8.0], 0.05%Tween 20, 20mM imidazole [pH 8.0]) and thenwith
native wash buffer (0.1 M NaH2PO4, 0.1 M Tris-HCl [pH 8.0]. Protein was dissolved in Laemmli buffer and resolved by SDS-PAGE.
Monoclonal antibody HA.11 (901514, Cambridge Bioscience) was used to detect ubiquitinated 4E-BP2.
In vitro ubiquitination assay
In vitro ubiquitination assay was performed in 100 mL reaction mixture at 37C for 2 h. The reaction mixture included 100 ng purified
human recombinant 4E-BP2WT and N99D/N102D, 100 ng purified human recombinant UBE1 (E1 enzyme, E-304, BostonBiochem),
500 ng UbcH7/UBE2L3 (E2 enzyme, E2-640, BostonBiochem), 10 mg ubiquitin (U-530, BostonBiochem), 2.5 mg purified human re-
combinant CUL4B (E3 enzyme, H00008450-P01, Novus Biologicals), 50 ng purified human recombinant DDB1 (ab114333, abcam),
purified human recombinant Raptor (H00057521-P01, Novus Biologicals) in an ATP-regenerating system [50 mM Tris-HCl, pH 7.6,
10 mMMgCl2, 2 mM ATP (R0441, ThermoFisher Scientific) 10 mM creatine phosphate (10621714001, Merck), 3.5 U/mL creatine ki-
nase (10127566001, Merck) and 0.6 U/mL inorganic pyrophosphatase (M0361S, New England Biolabs)], in the presence of 5 mM
ubiquitin aldehyde (U-201, BostonBiochem) and 50 mM MG132. Proteins were dissolved in Laemmli buffer and resolved by SDS-
PAGE.
Proteasome activity assay
The chymotrypsin-like activity of the proteasome was determined using a specific proteasome substrate (Proteasome Substrate III,
Fluorogenic, Suc-Leu-Leu-Val-Tyr-AMC, 539142-5MG, Calbiochem). Synaptoneurosome fractions (10 mg) were incubated with the
substrate (40 mM) in 100 mL of proteasome assay buffer [0.05 M Tris-HCl (pH 8.0), 0.5 mM EDTA, 1 mM ATP, and 1 mM dithiothreitol
(DTT)] at 37C for 1 h. After the incubation, proteasome activity was measured every 20 min and the plate was kept at 37C. The
fluorescence of the released AMCwas detected using a fluorescence microplate reader system (GloMax Explorer MultimodeMicro-
plate Reader, Promega) at 380-nm excitation and 460-nm emission wavelengths.
NF-kB reporter luciferase assay
The NF-kB reporter (luc)-HEK293 cell line (BPS Bioscience) contains a firefly luciferase gene driven by four copies of NF-kB response
element located upstream of the minimal TATA promoter. Stable cells were transfected with 4E-BP2 isoforms as above and supple-
mented with 100 ng pTK-RL (Gkogkas et al., 2008) for 48h and lysed 24h later (+/ TNFa 1nm) in lysis buffer from the Dual Luciferase
Reporter Assay kit (Promega). Firefly and renilla luminescence were measured using a FLUOstar OPTIMA micro-plate reader (BMG
LABTECH). Firefly luciferase luminescence values were normalized to renilla firefly luminescence values and are averages of four
experiments.
Immunoblotting
HEK293H cells, dissociated cortical neuronal cultures or mouse/human tissue were lysed in RIPA buffer (150 mM sodium chloride,
1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) supplemented with protease and phosphatase inhibitors
(Roche) unless otherwise specified, in a Dounce glass homogenizer by applying30 strokes, on ice. Samples were further incubated
on ice for 15 min, with occasional vortexing, and cleared by centrifugation for 20 min at 16,000 x g at 4C. The supernatant was used
for western blotting after the protein concentration of each sample was determined by measuring A280 absorbance on a NanoDrop
(ThermoFisher Scientific). 50 mg of protein per lane was prepared in Laemmli sample buffer (50 mM Tris, pH 6.8, 100 mM DTT, 2%
SDS, 10% glycerol, 0.1% bromophenol blue), heated to 98C for 2 min, and resolved on 10%–16% polyacrylamide gels. Proteins
were transferred to 0.2 mm nitrocellulose membrane (Bio-Rad), blocked in 5% milk in TBS-T (10mM Tris, pH 7.6, 150mM NaCl,
0.1%Tween20) for 1 h at room temperature, incubatedwith primary antibodies 1:1000 (1%BSA in TBS-T containing 0.02%Na azide)
overnight at 4C and with secondary antibodies 1:5000 for 1 h at room temperature (5%milk in TBS-T). Between incubations, mem-
branes were washed three times in TBS-T. For reprobing, membranes were stripped by incubation with 0.2 M NaOH for 10 min andCell Reports 29, 3620–3635.e1–e7, December 10, 2019 e4
blocked with 5% milk in TBS-T for 1 h. Proteins were visualized using enhanced chemiluminescence (1705061, Biorad and 32106,
ThermoFisher Scientific) after exposing on X-ray films (34089, ThermoFisher Scientific) processed with an Ecomax Film Processor
(ProTec).
Immunoprecipitation
HEK293H cells were transfected with 5 mg DNA of the HA plasmids expressing either WT or 2D (the amount of DNA was balanced to
achieve the same intensity/protein expression for each plasmid) and 10 mg of Myc – Raptor. After 48 h of transfection, cells were
rapidly homogenized in ice cold lysis buffer (50mMHEPES pH 7.5, 1%CHAPS, 150mMNaCl, protease and phosphatase inhibitors),
on ice. Homogenates were incubated at 4C with constant rotation and centrifuged at 15,000 x g for 10 min at 4C. Supernatants
were collected and precleared with 100 mL of protein G agarose beads (37478S, Cell Signaling Technologies). 7 mg of precleared
supernatant was incubated with 3 mg of c-myc antibody [(9E10), sc-40, Santa Cruz] for 30 min at 4C, followed by incubation with
protein G agarose beads overnight at 4C. Beads were then centrifuged at 3,500 x g for 1 min at 4C and washed three times
with lysis buffer for 10 min. Immunoprecipitates were dissolved in 2X Laemmli buffer, resolved by SDS-PAGE and probed with
anti-myc and anti-HA antisera.
Phosphatase Treatment
Whole brains or cortical neuronal cells at the indicated ages were homogenized in 1X phosphatase buffer (PMP Buffer, B0761S, New
England Biolabs) containing protease inhibitors (Roche), supplemented with 1 mMMnCl2 (B1761S, New England Biolabs). Extracts
were diluted to 2 mg/ml in a total volume of 90 ml. 9 mL of the phosphatase (P0753S, New England Biolabs) was added per sample and
the samples were incubated at 30C for 45 min. The reactions were stopped by addition of 5X SDS-PAGE Laemmli sample buffer.
Isolation of Synaptoneurosomes
Synaptoneurosomeswere prepared from freshmouse brain tissue. Cortices were isolated fromWTmice aged 8-12 weeks, and each
hemisphere was homogenized in ice–cold sucrose buffer (320mM Sucrose, 5mM Tris, 1mM EDTA, pH 7.4) and the homogenates
were centrifuged for 10 min, at 1000 x g, 4C. The supernatant was kept on ice and the pellet was resuspended in sucrose buffer
and centrifuged again for 10 min, 1000 x g at 4C. The pooled supernatant was then centrifuged for 10 min, at 21,000 x g at 4C
to pellet out crude synaptoneurosomes. Crude synaptoneurosomes were resuspended in 3% Percoll (GE Healthcare) and layered
on a discontinuous 10%–24% Percoll gradient. The material between layers 24% and 10%was collected, resuspended in Ionic Me-
dia (20mMHEPES, 10mMGlucose, 1.2mMNa2HPO4, 1mMMgCl2, 5mMNaHCO3, 5mMKCl, 140mMNaCl, pH 7.4) and centrifuged
at 21,000 x g, for 15 min at 4C.
Immunofluorescence and Confocal Imaging
Primary cortical neuronal cultures were prepared from E17 mouse embryos. Cells were plated on coverslips, previously coated with
0.05 mg/ml poly-D-lysine (P7886, Merck) for 2 h and 10 mg/ml laminin (23017-015, Invitrogen) for 1 h, at a density of 80,000 cells/well
in 24-well dishes. Four days after plating, neurons were co-transfected with 0.25 mg of HA - 4E-BP2WT plasmid and 0.25 mg of FLAG
– 4E-BP2N99D/N102D using 0.5 mL of Lipofectamine 3000 in pre-warmedOpti-MEM supplemented with 1x Glutamax. Following 1 h
of transfection, neurons were returned to conditioned media. Neurons were fixed at DIV16 in 4% PFA in phosphate-buffered saline
(PBS) for 8 min and washed three times for 5 min in PBS. Cells were permeabilised with 0.1% Triton X-100 for 5 min and blocked with
2.5%BSA in 1x PBS for 30min. Then, cells were incubated with 1:50 anti-FLAG TagMonoclonal Antibody (L5), Alexa Fluor 488 (MA1-
142-A488, ThermoFisher Scientific) and 1:25 anti-HA Tag Monoclonal Antibody (2-2.2.14), DyLight 680 (26183-D680, Thermo Fisher
Scientific) for 2 h. Coverslips were incubated with DAPI 1:10000 (4’,6-Diamidino-2-Phenylindole, Dihydrochloride, D1306, Thermo
Fisher Scientific) for 5 min. Then, the coverslips were washed and mounted with Lab Vision PermaFluor Aqueous Mounting Medium
(TA-030-FM, Thermo Fisher Scientific). Images of co-transfected neurons were acquired on a Nikon A1R microscope using a 60X
objective. For the quantification and colocalization analysis experiments, z stack images were taken with a pixel size of 60 3
60 nm2 and z-step size of 150 nm. Excitation laser wavelengths for the different samples were: 488 nm for FLAG tag, 680 nm for
HA tag, and 401.5 nm for DAPI. Microscope control and image acquisition were done using the NIS-Elements-v4.13 software.
Imaging analysis
Deconvolution of confocal images was performed using Huygens Essential (Huygens Software 4.5.1p3) before subsequent analysis.
Co-localization analysis was performed on 3D, deconvolved images and quantified using ImarisColoc (Imaris v8.2.1, Bitplane Inc,
software available at https://imaris.oxinst.com). All image analysis and quantification of images acquired with confocal microscopy
were performed on deconvolved images without any additional processing. Brightness and contrast settings were adjusted in Imaris
for presentation purposes only.
Ribosome profiling
Components of the Epicenter TruSeq Ribo Profile (Mammalian) Kit (Illumina, RPHRM12126), with some modifications, were used to
generate sequencing libraries. In brief, polysomes were extracted from primary neuronal cultures infected with 4E-BP2-expressing
viruses. A partial volume of these lysates was digested with TruSeq Ribo Profile Nuclease (RNase I) (Ribosome Protected Fragments,e5 Cell Reports 29, 3620–3635.e1–e7, December 10, 2019
RPF), while another part of the lysate was kept as an internal transcription control (Total mRNA). After digestion, RPFs were purified
on MicroSpin S-400 columns as described in the kit to enrich for small RNA fragments (28-30 nt).
All samples (RPF and Total mRNA) were depleted of ribosomal RNA using the Ribo-Zero Gold (Human/Mouse/Rat) Kit (Illumina,
MRZG126). RPFs only were purified on a 15% TBE-Urea polyacrylamide gel (EC68852BOX, ThermoFisher Scientific), selecting
bands running between 28 and 30 nt. Only Total RNA samples were heat fragmented. All samples were end-repaired using TruSeq
Ribo Profile Polynucleotide kinase. Samples were quantified using the Agilent Small RNA Kit (Agilent Technologies). For library gen-
eration, NEXTflex Small RNA Sequencing Kit v3 for Illumina Platforms (Bioo Scientific) was used. Input was balanced between sam-
ples to ensure similar output. Themanufacturer’s protocol was followed. In brief, an adenylated 30 adaptor was ligated, followed by an
adenylated 50 adaptor ligation. The RNA fragments were then reverse transcribed into cDNA and amplified using PCR (18 cycles).
During the PCR, individual samples were barcoded for multiplex sequencing using the barcoding primers compatible with Illumina
sequencing, included in the kit. The PCR products were size selected on an 8% native TBE-PAGE gel (EC62152BOX, ThermoFisher)
and purified from the gel according to the manufacturer’s instructions. The cDNA libraries were then analyzed for size, quantity and
quality using the Agilent High Sensitivity DNA kit (Agilent Technologies).
Samples were balanced and pooled for sequencing with Edinburgh Genomics on NovaSeq S1 flow cells yielding 50 bp paired-end
reads. Raw sequencing data were de-multiplexed by the sequencing facility. Sequences were analyzed using a custom developed
bioinformatics pipeline adapted from Ingolia et al. (2012) and previously described in Amorim et al. (2018). Adapters were removed
from raw sequencing reads using FASTX Toolkit and undesired rRNA and tRNA sequences were removed via alignment using bow-
tie. Filtered reads were mapped to an indexed reference genome using STAR and raw counts per gene obtained from the aligned
data.
Raw counts were converted to Reads Per Kilobase of transcript per Million mapped reads (RPKM) for each gene i in RPF and total
RNA using the formula:
RPKMi =
counti
lengthi
103

Pk
i = 1
counti
106
For each gene, the translational efficiency (TE) was calculated by dividing the RPKMvalues of the RPF libraries by the RPKMvalues of
the total RNA libraries. The R package Xtail (Xiao et al., 2016) was used for formal testing of the TE ratio significance in pairwise com-
parisons of treatments. Changes in transcription (total RNA) between predefined pairwise comparisons of treatments were analyzed
using methods of microarray normalization as described in Amorim et al. (2018). False-discovery rates (FDR) were calculated from p
values derived with the z-score as in Reiner et al. (2003). Genes with < 40 reads were discarded. Raw, aligned RNaseq data will be
deposited to NCBI Gene Expression Omnibus (GEO) and are currently available from the following link: https://datasync.ed.ac.uk/
index.php/s/AvexXZSretGYl2X and the password is: deamidation
UTR analysis
UTRs were obtained from Biomart ENSEMBL (Yates et al., 2016) using the GRCm38.p6 version of the mouse genome. 50 UTRmotifs
were predicted using UTRscan, pooling data from UTRdb (Grillo et al., 2010). Data Length in BP and %GC content were calculated
using free Python-based scripts (Multifastats; https://github.com/davidrequena/multifastats).
Gene Ontology and Pathway Analysis
GeneOntology (GO) and Pathway Analysis were performed using, respectively, the online tool DAVID version 6.8 (Huang et al., 2009),
and the Ingenuity Pathway Analysis Software (IPA; QIAGEN; version 42012434). Differentially translated genes were submitted to IPA
and subjected to Core Analysis with analysis parameters set to include Direct and Indirect Interactions and Experimentally Observed
data only. Network data were obtained for all datasets and Molecular Activity Predictor (MAP) analysis was applied based on the
differentially regulated genes belonging to each individual network. For GO analysis, filtered gene lists set to highlight genes differ-
entially repressed by WT or 2D were individually submitted to DAVID and GO annotation gathered for Biological Function, Molecular
Function and Cellular Component.
Protein expression and purification
Recombinant proteins were expressed in Escherichia coli BL21(DE3) (C600003, ThermoFisher) by growing transformed cells in LB
medium at 37C, inducing with 1 mM isopropyl b-D-1 thiogalactopyranoside (IPTG, I6758, Merck). After 3 h of induction at 28C, the
cells were harvested, washed with 100 mM Tris-HCl (pH 7.5), 170 mM NaCl and lysed in 20 mM PBS, (pH 7.4), 270 mM NaCl, 5 mM
KCl, 1mMDTT, 0.1mg/ml lysozyme (L6876,Merck) by one freeze-thaw cycle, followed by sonication. Lysed cells were centrifuged at
16,000 x g for 30 min at 4C and the supernatant was loaded onto a glutathione-Sepharose resin (GE17-0756-01, GE Healthcare),
allowing the protein to bind for 4 h at 4C. The resin was then washed with 10mM PBS, (pH 7.4), 140 mM NaCl, 3 mM KCl and 1 mM
DTT. Recombinant His-tagged 3C protease was added to the resin and incubated for 18 h at 4C. Tagless protein was collected and
loaded onto a Ni-NTA resin (30230, QIAGEN) to bind the 3C protease. Tagless protein was eluted with 20 mM imidazole. Eluted frac-
tions were loaded onto a Superdex S200 16/600 column (GEHealthcare), equilibrated with 20mMTris-HCl pH 7.4 and 150mMNaCl.
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using a 3 kDa MWCO spin concentrator to 4-11 mg/ml. Protein concentration was determined by absorbance measurements at
280 nm and the protein identity was confirmed by tryptic in-gel digestion and mass spectrometry using the method described pre-
viously (Raasakka et al., 2015).
Protein samples used for NMR were prepared as stated above but expressed in M9 minimal medium supplied with N15 labeled
ammonium chloride. The buffer used in the final SEC purification step consisted of 20 mM PBS pH 7.4 and 150 mM NaCl.
Size exclusion chromatography - multi angle light scattering (SEC-MALS)
The molecular mass of 4E-BP2 was determined with SEC-MALS, using a miniDAWN Treos MALS detector (Wyatt). Protein concen-
tration wasmeasuredwith an online RI detector. The SEC column, Superdex S200 Increase 10/300 (GEHealthcare), was equilibrated
with 20mMTris-HCl (pH 7.4), 150mMNaCl at 4C. The SEC-MALS systemwas calibrated using ovalbumin, and the concentration of
the injected 4E-bP2 was 1.2 mg/ml.
Synchrotron radiation circular dichroism (SRCD)
Recombinant purified proteins were either diluted into a buffer (20 mM PBS pH 7.4, 150 mM NaF and 0.5 mM DTT) just before the
measurement or dialyzed against 20mM phosphate pH 7.5 for 20 h at 4C. The ellipticity of each sample wasmeasured between 170
and 280 nm in a quartz cuvette with a pathlength of 0.1 mm on the AU-CD beamline at ASTRID2 (ISA, Aarhus, Denmark) at 10C.
Sample concentrations were between 0.3-1.0 mg/ml and the same protein concentration was used, when different samples were
compared.
Small angle X-ray scattering (SAXS)
SAXS data were collected on the BM29 beamline (Pernot et al., 2013) of the European synchrotron radiation facility (ESRF, Grenoble,
France), using a wavelength of 0.9919 A˚. For batch measurements, 20 frames were collected with 0.5 s of exposure per frame at a
temperature of 10C. Sample concentrations were within a range of 0.5-10 mg/ml. SEC-SAXS was also performed using an Agilent
BioSEC-3 HPLC column, equilibrated with 20 mM Tris-HCl (pH 7.4), 150mMNaCl, collecting one frame/s. Data were processed and
analyzed using the ATSAS software suite (Konarev et al., 2003). The radius of gyration was calculated either based on the Guinier
region or using the Debye formula (Calmettes et al., 1994). 3D ab initio models were generated using DAMMIN (Svergun, 1999)
and GASBOR (Svergun et al., 2001).
Nuclear magnetic resonance spectroscopy (NMR)
Purified 15N labeled proteins (9mg/ml) weremeasured in a buffer consisting of 20mMPBS (pH 7.4), 150mMNaCl and 1mMDTTwith
10% D2O and 2,2-dimethyl-2-silapentane-5-sulfonate (0.1 mM), using an 850 MHz Bruker BioSpin 850 Ascend sepctrometer at
27C.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification of Immunoblotting
The intensity of each protein band was measured from original images (no brightness or contrast adjustments) with ImageStudio
Software (Li-COR Biosciences) in triplicate and averaged to minimize measuring variability. Loading controls were used in each
experiment. Data are shown as protein expression (arbitrary units) after normalization to control. For quantification of endogenous
4E-BP2 in brain, the intensity of the bottom bandwasmeasured forWT 4E-BP2 and the intensity of middle and top band correspond-
ing to single or double deamidated 4E-BP2 respectively, for 2D 4E-BP2.
Statistical Analysis and Experimental Design
Experimenters were blinded to the genotype during experimentation and data analysis. All data are presented as mean ± SEM (error
bars) and individual experimental points are depicted in column or bar graphs. Statistical significance was set a priori at 0.05 (n.s.:
non-significant). Where analysis of variance (ANOVA) is carried out the assumptions for normality (Shapiro-Wilk) and equality of var-
iances (Bartlett’s test) are met. No nested data were obtained in this study; we only collected one observation per research object.
The n number denotes biological replicates. No randomization was carried out for any of the experiments described here. Details for
statistical and post hoc tests used were provided within figure legends or the relative methods description and summarized in Table
S2; all data collected followed normal distributions, thus only parametric tests were used. Data summaries and statistical analysis
were carried out using Graphpad Prism 6 unless otherwise stated.
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